Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Preferred Stock Liabilities (2019 - 2020)

Keros Therapeutics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $55.8 million for Q1 2020.

  • For Q1 2020, Preferred Stock Liabilities rose 512.57% year-over-year to $55.8 million; the TTM value through Mar 2020 reached $55.8 million, up 512.57%, while the annual FY2019 figure was $19.9 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $55.8 million in Q1 2020 per KROS's latest filing, up from $19.9 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $55.8 million in Q1 2020 to a low of $9.1 million in Q1 2019.